

Table 9.25
All Lymphoid Neoplasms With Detailed Hodgkin Lymphoma Subtypes^a
SEER^b 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Both Sexes, 2010-2016

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)	Percent (95% C.I.)		
Lymphoid Neoplasm	188,530	72.2 (71.9 , 72.5)	90.7 (90.1 , 91.4)	79.4 (79.0 , 79.7)	62.9 (62.4 , 63.4)			
1 Hodgkin Lymphoma	14,617	87.4 (86.7 , 88.1)	98.0 (97.0 , 98.6)	90.8 (90.1 , 91.5)	59.6 (56.5 , 62.5)			
1(a) Classical Hodgkin lymphoma	13,594	86.6 (85.9 , 87.3)	97.7 (96.7 , 98.4)	90.4 (89.7 , 91.1)	56.8 (53.6 , 59.8)			
1(a)1. Lymphocyte-rich/mixed cellularity/ lymphocyte-depleted	2,016	84.0 (81.8 , 85.9)	98.9 (95.0 , 99.8)	88.2 (86.0 , 90.1)	64.0 (57.3 , 69.9)			
1(a)1.1 Lymphocyte-rich	414	90.2 (85.4 , 93.4)	96.7 (78.2 , 99.6)	95.2 (90.6 , 97.5)	68.0 (50.6 , 80.4)			
1(a)1.2 Mixed cellularity	1,484	84.0 (81.5 , 86.2)	99.3 (93.3 , 99.9)	87.6 (85.0 , 89.9)	65.3 (57.5 , 72.1)			
1(a)1.3 Lymphocyte-depleted	118	60.5 (50.0 , 69.4)	100.0 (- , -)	67.6 (54.1 , 77.9)	32.8 (18.3 , 48.1)			
1(a)2. Nodular sclerosis	7,568	91.5 (90.7 , 92.3)	98.4 (97.3 , 99.1)	93.1 (92.3 , 93.9)	62.5 (57.0 , 67.5)			
1(a)3. Classical Hodgkin lymphoma, NOS ^c	4,010	78.5 (76.9 , 80.0)	94.4 (90.3 , 96.8)	85.8 (84.1 , 87.3)	48.3 (43.5 , 52.9)			
1(b) Nodular lymphocyte predominant Hodgkin Lymphoma	1,023	97.1 (95.2 , 98.3)	100.0 (- , -)	96.2 (93.9 , 97.7)	94.6 (84.3 , 98.2)			
2 Non-Hodgkin lymphoma	170,050	71.2 (70.9 , 71.5)	89.1 (88.2 , 89.8)	77.9 (77.6 , 78.3)	63.5 (63.0 , 64.0)			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	384	74.7 (67.4 , 80.5)	100.0 (- , -)	82.0 (75.2 , 87.2)	59.9 (43.1 , 73.2)			
4 Lymphoid neoplasm, NOS ^c	3,479	52.0 (49.9 , 54.1)	82.3 (74.0 , 88.2)	67.1 (64.2 , 69.8)	39.9 (37.0 , 42.7)			

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). [Expected survival rates](#) are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^c NOS = Not otherwise specified.

- Statistic not displayed due to less than 25 cases.